Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes

Lenalidomide, an oral immunomodulatory agent, has received approval in the USA from the Food and Drug Administration (FDA) for the management of myelodysplastic syndromes (MDS) classified by the International Prognostic Scoring System (IPSS) as low risk or intermediate-1 risk and with a deletion 5q...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Giagounidis, Aristoteles, Fenaux, Pierre, Mufti, Ghulam J., Muus, Petra, Platzbecker, Uwe, Sanz, Guillermo, Cripe, Larry, Von Lilienfeld-Toal, Marie, Wells, Richard A.
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer-Verlag 2008
Témata:
Review Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2275303/
https://ncbi.nlm.nih.gov/pubmed/18265982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-008-0449-0
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky